Trimetrexate Appears Beneficial in Colorectal Cancer

Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

PHILADELPHIA--The addition of trimetrexate (NeuTrexin) to the standard chemotherapeutic regimen of fluorouracil and leucovorin in patients with metastatic colorectal cancer resulted in an improved response rate with no greater toxicity in a study reported at the Oncology Nursing Society meeting.

Nurses administering this treatment should monitor patients carefully,assess quality of life factors, and take a proactive approachto managing any side effects, said Janet Cogswell, RN, and ShirleyHwang, RN, of the Veterans Affairs Medical Center, East Orange,NJ.

In this phase II multicenter trial, trimetrexate plus fluorouracil/leucovorinproduced an overall response rate of 48%. The findings confirmearlier trials of colorectal patients, both previously treatedand untreated, that achieved overall response rates ranging from20% to 53%.

In the study, 36 patients were treated on an 8-week cycle (6 weekson, 2 weeks off). On day 1, a 110 mg/m² IV infusion of trimetrexatewas given over 60 minutes; on day 2, leucovorin (200 mg/m²IV infusion) was given over 60 minutes, immediately followed byfluorouracil (500 mg/m² IV bolus). On days 2 and 3, sevendoses of oral leucovorin (15 mg) were given every 6 hours, starting6 hours after the fluorouracil bolus.

Toxicities were comparable to those in the standard two-drug regimen,Ms. Cogswell said, but, she added, patient education and a teamapproach to toxicity management are critical.

"Nurses play a major role in education," Ms. Cogswellsaid. "It's important to teach patients up front about possibletoxicities and how to manage them at home, such as taking Compazine[pro-chlorperazine] for nausea/vomiting."

The most common side effect in the trimetrexate regimen was diarrhea(60% of patients). Patients should be instructed to take loperamideat the first loose bowel movement, and those who have more thansix or eight loose bowel movements in a day should be hospitalizedimmediately and treated for dehydration, the researchers advised.

A few histamine (possibly allergic) reactions, characterized byrigors, occurred, although not until patients had returned home,"so it's very important that they be encouraged to tell thetreatment team what side effects, if any, they are having aftertreatment and be taught how to handle them," Ms. Cogswellsaid. Di-phenhydramine, she said, is effective in controllingthe histamine reaction.

The study also assessed patients' quality of life every 4 weeks,using Symptom Distress Scale data. Physical, emotional, socialand functional issues were examined, as well as the quality ofpatients' relationships with their physician.

"Quality of life is multidimensional, based on the patient'sown perceptions and no one else's," Ms. Hwang stressed. "Inthis study, patients reported an increased appetite and improvedperformance status, benefits that appear to be due to the additionof trimetrexate."

Trimetrexate (with concurrent leuco-vorin) is commercially availableas an alternative to trimethoprim-sulfameth-oxazole for the treatmentof Pneumocystis carinii pneumonia. The agent was developedto address problems with classical antifolates such as methotrexate,the researchers said. It has a wider spectrum of activity thanmethotrexate and is active against cancers that have acquiredresistance to the parent drug.

A double-blind, multicenter phase III trial comparing trimetrexate/fluorouracil/leucovorinwith the standard regimen is underway, with preliminary resultsexpected in about a year, the investigators said. The EORTC hasinitiated a similar trial in Europe.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content